UCB (UCB.BR) and Collegium (COLL): the top pharma stocks in 2026

2026-06-24 · By Lubin Danilo, founder of Lubin Investment

Out of hundreds of pharmaceutical stocks, only two pass all ten of my criteria in 2026: UCB SA (Brussels, neurology and immunology specialist) and Collegium Pharmaceutical (NASDAQ, chronic pain management). Opposite models, the same financial robustness.

Key takeaways: only two pharmaceutical stocks score 10/10 in my screener as of June 2026: UCB SA and Collegium Pharmaceutical. UCB is built on long-term R&D (Bimzelx in immunology, 43.4% FCF/share CAGR). Collegium optimizes approved drugs (Xtampza ER, Belbuca, AZSTARYS), with a 36% FCF margin and a valuation below 5x free cash flow vs sector median of 27x.

UCB: science compounding into cash

UCB's free cash flow per share grew 43.4% per year over five years, driven by Bimzelx's launch in psoriasis and expanding indications. FCF margin 23.8%, net cash positive. The stock trades at ~27.5x annual free cash flow, close to my calculated buy price of ~270 EUR. See my <a href="/blog/ucb-ucbbr-pharma-belge-immunologie-analyse-fondamentale">full UCB analysis</a>.

Collegium: capital allocation over R&D risk

Collegium avoids pipeline risk by acquiring and optimizing already-approved drugs. Xtampza ER and Belbuca generate 36% FCF margins, Cash ROCE of 43%. The stock trades below 5x FCF vs a ~27x sector median. My calculated buy price: ~89 USD vs current ~35.58 USD. See my <a href="/blog/collegium-pharmaceutical-coll-analyse-fondamentale-pharma">full Collegium analysis</a>.

The method: quality before price, always

Both companies pass all 10 of my criteria, but for different reasons. The core question in pharma: does the company generate real cash today, not just pipeline promises? UCB and Collegium both answer yes. Explore both and compare via <a href="/analyser">my screener</a>.

FAQ

Why do so few pharma stocks pass your criteria?

R&D spending depresses margins and FCF for years, patent cliffs create structural revenue uncertainty. My method demands demonstrated profitability and cash growth, not potential.

UCB or Collegium?

Very different bets: UCB is larger, costlier, pipeline-driven with little valuation margin. Collegium is tiny, deeply undervalued per my model, but in a regulated opioid market.

Is 4.9x FCF really possible for Collegium?

Per my screener data at June 24, 2026. Low multiple reflects either skepticism on opioid revenues or small-cap indifference. A low multiple is only a good deal if quality holds.

Analyser une action sur Lubin Investment

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I have analyzed stocks through their fundamentals for several years and invest my own money with this method. I codified it into a tool that judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).